Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 20 of 20 results for dupilumab

  1. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)

    This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

    Antimicrobial prescribing guideline
    Published
    2 March 2021
    View recommendations

    Sections for NG190

  4. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development [GID-TA11272] Expected publication date: TBC

    Technology appraisal guidance
    In development